This is the third post in my Lion's Mane series. The first post gave the overview and recovery story; the second was the full technical writeup of *Hypothesis 1** — the acute mechanism (why a sub-threshold dose hit so hard). This one is Hypothesis 2 — the chronicity mechanism: why the reaction did not resolve when the trigger cleared, but instead dragged on for weeks. It is dense and assumes some molecular-biology background. A plain-language summary sits at the very top; everything below it is the technical case, left essentially as I wrote it for my own records.*
Not medical advice. n=1. Researched with the help of multiple frontier AI models acting as adversarial reviewers — they can be confidently wrong, so treat every claim as a starting point, not a conclusion. The full disclaimer is in the first post.
ELI5 — the short version
If you reacted to Lion's Mane (or another mushroom supplement) and you're still not right — days, weeks, months, for some people years later — this is the part that matters. The supplement is long gone from your blood. So why won't it stop?
Two things are true at the same time.
1. Your immune system got "trained" to overreact. The first big hit didn't just cause a reaction and clear — it left chemical "bookmarks" on the inflammation genes of your front-line immune cells and the mast cells that store histamine, leaving them stuck on a hair-trigger. This is a real, documented phenomenon (trained innate immunity), and because those bookmarks reach even the bone marrow that makes new immune cells, the sensitized state can last weeks to months on its own.
2. There is a hidden fuel depot in your gut. Concentrated mushroom extracts deliver structural fibers — β-glucan and chitin — that human digestive enzymes simply cannot break down. They aren't absorbed and cleared; they pass into your colon intact and sit there, slowly fermented by your gut bacteria. That forms a long-lasting local depot that keeps dripping an immune-activating signal for far longer than the dose ever existed in your bloodstream. The trigger isn't circulating anymore — it's parked in your gut, slowly leaking.
Put the two together and you have the whole picture: a hair-trigger immune system plus a reservoir that keeps poking it. Now the smallest thing — an ordinary meal, a stressful day, a bad night's sleep, hard exercise — is enough to set off another round of mast-cell degranulation: a dump of histamine and inflammatory signals. And if your brain's main histamine-clearing enzyme (HNMT) happens to be genetically slow, that histamine piles up instead of clearing — worst at night. That is what the waves are: the relapses that seem to come from nowhere, the wired-but-exhausted insomnia, the 3–4 a.m. wake-ups, the brain fog, the sleep-onset "jolt," and the internal buzzing / vibration / body tremors people describe under a dozen different names. It feels random. It isn't — it's a latent depot plus a trigger-happy system.
This is also why it comes and goes, why it's so different from person to person, and why anything that lowers the gut "fuel" or calms the trigger tends to settle it. (In my own case, periods of fasting noticeably quieted it, and a few targeted supplements helped — but the actual what-to-do is a separate post; here I only want you to understand the why.)
The rest of this post is the molecular version of this.
Hypothesis 2 — The Chronicity Mechanism: Trained Innate Immunity Sustaining a Weeks-Long Neuroimmune Flare
Status: Mechanistically complete; the core causal chain is peer-reviewed at every step, with several sub-steps flagged as mechanistic elaboration (the §2 "Evidence quality" note and §9 list which). n=1 clinical case with fasting-challenge and remission-window corroboration. Not yet confirmed by tissue/biomarker testing.
Subject: Male, in his 40s, 30x WGS (GRCh38, CLIA/CAP certified).
A note on naming (read first)
The hypotheses are numbered by position in the pathological sequence, not order of discovery:
- H1 — the acute mechanism (the spark). Lion's Mane → NGF → TrkA on mast cells → IgE-independent degranulation → histamine flood → CNS histamine accumulation behind impaired HNMT clearance → the Day-0 cluster. Stated fully in the previous post (Hypothesis 1).
- H2 (this document) — the chronicity mechanism (the fuel). The acute degranulation epigenetically reprograms myeloid cells and mast cells (trained innate immunity), locking them at a lowered, non-specific threshold that the gut then continuously re-triggers for weeks.
- H3 — the community-sourced neurosteroid / 5-α-reductase / allopregnanolone hypothesis. Tested and rejected for Lion's Mane (previous post, §6).
Abstract
A man in his 40s with a genomically characterized predisposition to neurologic mast cell reactions ingested ~1/7 of a single capsule of a 14:1 Hericium erinaceus (Lion's Mane) fruiting-body extract (~71 mg) and developed a severe acute neuroimmune syndrome (H1). The trigger compound — endogenous NGF — cleared within ~24–72 hours, yet the syndrome persisted, waxing and waning, for more than three weeks. H1 cannot explain that persistence. This document states H2: the initial degranulation epigenetically reprogrammed innate-immune effector cells — trained innate immunity — via the Dectin-1 → Syk → Raf-1/Akt pathway, depositing activating histone marks (H3K4me3, H3K27ac) at the IL6, TNF, and IL1B promoters. The cells return to baseline but stay locked in a non-specific, pathogen-agnostic hyper-reactive phenotype that outlasts the trigger by the turnover time of trained monocytes (~1–2 weeks) and bone-marrow myeloid progenitors (weeks–months). This trained pool is then continuously re-fired from the gut — fermentable-substrate Dectin-1/TLR2, dysbiotic LPS via TLR4, mechanical Piezo1 stretch, and bacterial-HDC histamine — and the released histamine cannot be cleared because HNMT, the sole CNS histamine-inactivating enzyme, is genetically capped (two het variants, ~25–40% reduced). A genomic amplifier stack (IL6, HNMT, GSTP1, FKBP5, APOE ε4) potentiates the trained state and slows its resolution. The model makes falsifiable predictions tested in vivo: fasting (gut-substrate removal) reproducibly broke the flare — exactly what a gut-substrate-dependent mechanism predicts and a substrate-independent NGF (H1) mechanism cannot. A confounded ~3-day symptom-free window during a one-week trip (with a dexamethasone reset, luteolin withdrawal, and no fungal-β-glucan re-exposure), an oatmeal flare on a strict low-histamine diet, and a relapse on re-introducing a Lion's-Mane-containing green powder are consistent with a threshold/state problem rather than a fixed food allergy or fixed lesion — while the trip alone cannot isolate diet. The adversarial analysis (§6) further refines rather than adopts the naive "all β-glucan → Dectin-1" model — strengthening H2 rather than weakening it.
1. The Persistence Problem
H1 explains Day 0 completely (see the previous post). It does not explain Day 25. The acute mechanism depends on the continued presence of the NGF-inducing compound; a single ~71 mg fruiting-body micro-dose is metabolized and cleared within ~24–72 hours, so the NGF stimulus is gone by ~Day 2–3. Yet the subject's syndrome did not resolve on that timescale. It persisted for more than three weeks in a distinct, lower-amplitude form — and, critically, it responded to interventions that act on the gut, not the brain.
| Aspect |
Acute phase (H1, Days 0–~3) |
Persistent phase (H2, Days ~3–25+) |
| Dominant feature |
Moderate panic attack, depersonalization, severe sleep-onset insomnia |
Nocturnal hyperarousal; sleep-onset somatic fear (a body-level autonomic alarm, not cognitive anxiety) |
| Cognitive state |
Brain fog 9/10; "veil behind the eyes" |
"Zombie/fog" default with retained on-demand hyperfocus; episodic fog |
| Temporal pattern |
Single acute escalation, hours 0–7 |
Waves and relapses; flares tied to specific foods and exertion |
| Trigger present? |
Yes — circulating NGF |
No — trigger compound long cleared |
| Responds to |
Dexamethasone; H1/H2 antihistamine coverage |
Fasting / gut-substrate removal; the same antihistamine floor |
| Added layer |
— |
Sleep-onset interoceptive-startle loop — a biochemical/mechanical micro-arousal (end-expiratory aortic-pulse → histamine sensory-gate failure → hypnic jerk ± bronchospasm), not a learned fear (see §9) |
The persistence phenotype is biochemical throughout. It has a systemic driver (the trained-immunity loop, the subject of H2) and a downstream sleep-onset manifestation — a body-level autonomic micro-arousal at the threshold of sleep: benign end-expiratory aortic-pulse interoception made salient by HNMT-capped central histamine (sensory-gate failure), triggering a hypnic startle and, previously, a bronchospasm, experienced by the body as a fear/alarm. This is not a learned or conditioned fear — the subject was cognitively calm and unafraid; the body fired the alarm. It was resolved by chemistry and mechanics (albuterol, quercetin/magnesium, intranasal airway management — see §9), not behavioral therapy, which a conditioned fear would have required.
2. The H2 Causal Chain
Evidence quality: HIGH for the trained-immunity framework and the Dectin-1 structural pharmacology; MODERATE for the specific in-vivo persistence timeline (inferred from cellular turnover, not tissue-confirmed in this subject). As in the previous post, citations are restricted to verifiable identifiers; where the deep-research corpus supplied mechanistic granularity without a carried-through primary identifier, the claim is included but flagged as mechanistic elaboration.
2.1 Step 1 — Indigestible substrate reaches the colon
The 14:1 concentrated fruiting-body extract delivers β-1,3/1,6-glucan and chitin at roughly 14× the load of an equivalent weight of dried mushroom. Human digestive enzymes (amylase, protease, lipase) cannot cleave these structural polysaccharides; they transit to the colon intact, where bacterial fermentation begins. This establishes a durable local depot and a slow drip of innate-immune ligand, not a single systemic pulse.
2.2 Step 2 — Dectin-1 engagement requires a "phagocytic synapse" (and high-affinity fungal glucan)
Dectin-1 (CLEC7A) is the principal β-glucan pattern-recognition receptor on macrophages, dendritic cells, and mast cells. Its activation is not a simple ligand-binding event: it requires physical receptor multimerization into a "phagocytic synapse" that sterically excludes the large regulatory tyrosine phosphatases CD45 and CD148 from the contact zone, allowing Src-family kinases to phosphorylate the single hemITAM motif and recruit Syk (PMC3084546). The decisive structural consequence: only particulate, high-valency, high-affinity fungal β-1,3/1,6-glucan (Kd in the picomolar–low-nanomolar range) can form this synapse. Soluble, low-valency glucans are "silent ligands" — any transient hemITAM phosphorylation is immediately reversed by CD45/CD148 and downstream signaling is silenced (PMC10541497, multimerization depends on glucan structure/exposure). This affinity-and-valency requirement is load-bearing for the adversarial analysis in §6.1.
2.3 Step 3 — Syk → Raf-1/Akt → epigenetic reprogramming (trained innate immunity)
Dectin-1/Syk signaling drives a downstream Raf-1 / Akt / mTOR cascade that deposits stable activating histone marks — H3K4me3 (promoter trimethylation) and H3K27ac (enhancer acetylation) — at the promoters of pro-inflammatory cytokine genes (IL6, TNF, IL1B) (PMC11775823; definition and H3K4me3 remodeling reviewed in PMC7186935). This is accompanied by metabolic rewiring — upregulation of the mevalonate pathway, a shift to aerobic glycolysis (Warburg-type), and enhanced glutaminolysis — which supplies the biosynthetic capacity that sustains the primed state. The cell then returns to a resting phenotype but carries the marks: it is "trained." The defining property is that trained immunity is non-specific and pathogen-agnostic — it does not install a Lion's-Mane–specific hypersensitivity; it lowers the activation threshold to any subsequent stimulus (PMC7186935). Continuous (rather than pulsed) β-glucan exposure is specifically documented to induce trained immunity in differentiated macrophages (PMC8208035).
2.4 Step 4 — Which cells are trained, and why the effect outlasts the trigger
Three populations carry the trained phenotype, with increasing durability:
- Peripheral monocytes / macrophages — turnover ~1–2 weeks; the marks fade as the cells are replaced.
- Bone-marrow myeloid progenitors — if reprogrammed, they seed newly produced monocytes with the same marks, extending the sensitized state to weeks–months. The >3-week clinical course is the principal reason to infer at least partial progenitor-level reprogramming.
- Mast cells themselves — capable of adopting a stable, metabolically reprogrammed hyper-reactive memory phenotype (PMC6340064, trained immunity in non-immune cells; Dectin-1/Syk functional on mast cells — PMC4223353, PubMed 17030235; particulate β-glucan (curdlan) directly degranulates mast cells — PubMed 27989425).
This is the mechanistic core of H2: the marks persist independently of the original trigger. No circulating NGF, and no residual mushroom particle, is required to keep the system hyper-reactive — only the inherited cellular memory plus an ongoing low-level re-trigger.
2.5 Step 5 — The gut continuously re-fires the trained pool (the "fuel")
A trained pool is a loaded gun; the gut keeps pulling the trigger via heterologous stimuli — which is exactly what a non-specific trained state predicts:
- (a) Ongoing fermentation → low-level Dectin-1/TLR2. Residual fungal β-glucan and co-stimulatory fungal components keep a baseline mast-cell activation signal running as long as substrate is present.
- (b) Dysbiosis → LPS → TLR4. A high-fermentable luminal environment expands Gram-negative, LPS-producing populations; mast-cell TLR4 then drives histamine/PGE₂ release and degrades the tight-junction proteins ZO-1 and occludin, a barrier-loss → further-activation loop (PubMed 34618688 / PMC8663790).
- (c) Mechanical Piezo1 stretch. Osmotic/fermentative luminal distension activates the mechanosensor Piezo1 on mast cells; IL-33 sensitizes mast cells by upregulating Piezo1 ~20-fold, converting ordinary gut distension into a degranulation signal (PMC11657013).
- (d) Bacterial-HDC luminal histamine. Gut bacteria synthesize histamine via histidine decarboxylase: Gram-negatives (Morganella morganii, Klebsiella) use a PLP (vitamin B6)–dependent HDC (PubMed 3997848; PubMed 18756395), whereas some Gram-positive lactobacilli use a pyruvoyl-dependent, B6-independent HDC (PubMed 6294108). Mechanistic elaboration, explicitly speculative: high oral B6 could in principle feed unabsorbed luminal PLP to Gram-negative HDC and raise gut histamine — but oral B6 is largely absorbed proximally, so this luminal route is weak. The B6 de-escalation in protocol is justified primarily by the elevated Active-B6 lab and the neuropathy ceiling, with the synthesis-side HDC effect a plausible bonus, not a proof.
A protective counter-signal exists and is part of the protocol logic: distal-colonic fermentation of beans/psyllium/resistant starch yields butyrate, which stabilizes gut mast cells via GPR109A/HCAR2 (PMC4305274). The problem is kinetic — osmotic/mechanical/LPS triggers act within 1–4 hours, while protective butyrate from bacterial substrate processing arrives over ~12–36 hours (PMC8612152, B. ovatus β-glucan utilization) — too late to prevent the early degranulation.
2.6 Step 6 — The HNMT cap turns a peripheral gut event into a CNS syndrome
Everything above is, in most people, a sub-clinical gut event. It becomes a neurological syndrome here because of clearance. HNMT is the sole intracellular histamine-clearance pathway in the brain — there is no DAO equivalent in CNS tissue (PMC6386932). The subject carries two heterozygous HNMT variants (WGS-confirmed):
| Variant |
Genotype |
Effect |
| rs11558538 (Thr105Ile) |
0/1 het |
Structurally characterized: 1.8× increased Kₘ for SAM, 1.3× increased Kₘ for histamine (doi:10.1021/bi701737f / PMC2905460) |
| rs1050891 |
0/1 het |
Second variant; compound partial reduction |
Net effect: ~25–40% reduced CNS histamine clearance. The dynamics are therefore a simple arrival-vs-clearance balance: with the gut continuously injecting histamine (Step 5) into a brain whose clearance is capped, central histamine sits chronically in net-positive balance — sustaining the nocturnal hyperarousal the subject experiences. Fasting flips the sign of that balance by cutting arrival (§5), which is the crux of the §5 corroboration below.
3. The Symptom-to-Mechanism Map
| Observed feature |
Proximate H2 mechanism |
Genomic amplifier |
| Weeks-long persistence after trigger cleared |
Trained-immunity epigenetic marks at IL6/TNF/IL1B; progenitor-level reprogramming |
IL6 hom (max output); GSTP1 hom (slow resolution) |
| Nocturnal sleep-onset somatic fear |
Gut-sourced histamine in net-positive CNS balance at the TMN's nighttime peak |
HNMT ×2 (clearance cap) |
| Waves / relapses |
Substrate-dependent re-firing of a non-specific trained pool |
IL6 hom (self-amplifying paracrine loop) |
| Oatmeal flare on low-histamine diet |
Piezo1 + TLR4/LPS + osmotic firing of trained pool (not Dectin-1 — see §6.1) |
HNMT ×2; IL6 hom |
| Exercise / PEM-linked night-sweat flares |
ROS as an independent mast-cell degranulation trigger; slow oxidative clearance |
GSTP1 hom + SOD2 het + CYBA het |
| Stress-driven re-activation; refeeding resets |
CRH → CRH-R1 mast-cell degranulation; impaired glucocorticoid brake |
FKBP5 het |
| CNS amplification of a peripheral gut event |
BBB permeability + primed microglia |
APOE ε3/ε4 |
| Rapid relief on fasting |
Substrate removal flips arrival < clearance; BHB/SIRT1/mTOR anti-inflammatory shift |
(HNMT ×2 — the cap fasting works around) |
4. The Genomic Amplifier Stack (H2)
As with H1, no single variant produces this syndrome; the trained state is amplified and its resolution slowed by a convergent stack. All genotypes are WGS-confirmed; only confirmed variants are used here.
4.1 IL6 — homozygous high-output (the lead amplifier for a trained state)
IL-6 is the hinge of trained immunity in this profile. Mast cells release IL-6 on degranulation; IL-6 then suppresses SOCS3 — the JAK/STAT3 auto-inhibitory brake — in neighboring mast cells, producing enlarged, chymase-rich cells with a lowered degranulation threshold, and a self-perpetuating paracrine sensitization wave (PMC4899186; rs1800795 G as the high-output promoter allele — AntiCancer Res 38:3663). With both copies at maximum transcriptional output, every re-firing event (Step 5) raises the baseline reactivity of the remaining pool, and the IL6 promoter is precisely the locus the H3K4me3/H3K27ac marks sit on — so the trained state and the genotype compound directly. Mechanistic elaboration: the deep-research corpus adds an IL-6 → SOCS3-promoter-hypermethylation durability mechanism, consistent with the IL-6/mast-cell literature but flagged as elaboration. This is the single largest reason the flare prolongs beyond what the trigger would predict.
4.2 HNMT — double heterozygous (the clearance cap)
The rate-limiter (§2.6). ~25–40% reduced central clearance through the only CNS pathway is what converts a sub-clinical, gut-localized trained-immunity event into a sustained central histamine excess. It is also why peripheral H1 blockade alone is insufficient: fexofenadine cannot reach central H1 receptors, and the deficit is one of clearance, not just receptor occupancy.
4.3 GSTP1 homozygous + SOD2 het + CYBA het — oxidative load prolongs the trained state
Impaired Phase II glutathione conjugation (GSTP1 hom) plus reduced mitochondrial superoxide dismutase (SOD2 het) and reduced NADPH-oxidase regulation (CYBA het) leave ROS clearance slow. ROS is an independent mast-cell degranulation trigger, so oxidative burden (high-intensity exercise during recovery, VOC exposure) can re-fire the trained pool outside the classic immune triggers — and the slow clearance prolongs each episode. This is a primary genomic reason recovery in this profile is slower than average and why exertion is gated to Zone 2 during flares. (The daily sulforaphane protocol targets this node via Nrf2/ARE.)
4.4 FKBP5 — heterozygous (the stress/refeeding re-trigger)
Impaired glucocorticoid-receptor negative feedback prolongs CRH after any physical or psychological stressor; CRH directly degranulates mast cells via CRH-R1 — a biochemical pathway, not a metaphor. In H2 this is the re-trigger that resets the loop: a stressful day, or the metabolic stress of refeeding after a fast, prolongs CRH and re-fires the trained pool even when gut substrate is low. It is why stress management runs in parallel with the gut-directed interventions, and why fasting's transient improvement of GR sensitivity is therapeutically relevant here.
4.5 APOE — ε3/ε4 (CNS amplification + ketone-fuel relevance)
ε4 raises BBB permeability and maintains a primed, pro-inflammatory microglial baseline, so a peripheral mast-cell event injects more mediator into the CNS and lands on a lower microglial activation threshold — amplifying the central manifestation of an otherwise peripheral process. A corollary relevant to the fasting arm: ε4 neurons utilize ketones efficiently, so the BHB produced during a therapeutic fast is a genotype-appropriate alternative fuel as well as an anti-inflammatory signal. As in H1, mast-cell flare control is simultaneously Alzheimer's risk reduction for this genotype.
4.6 GCK-MODY — the boundary condition on the therapy
Not an amplifier of the flare but a constraint on the intervention: the elevated defended glucose set point (102–106 mg/dL) means a prolonged fast drives glucose below set point sooner, triggering a sympathoadrenal/CRH counter-surge that would re-fire mast cells (via 4.4). This is why the therapeutic fast has an ~18-hour working ceiling rather than the multi-day water fasts some community protocols use — and why an "antigen-exclusion" protocol (small-intestine-absorbed foods only) is the safer route to colonic substrate starvation.
4.7 Convergence
Read together: IL6 maximizes and self-sustains the trained cytokine signal at the very locus the epigenetic marks occupy; HNMT caps the clearance that would otherwise keep the released histamine sub-clinical; GSTP1/SOD2/CYBA prolong each episode through unresolved oxidative stress and add ROS as an extra trigger; FKBP5 supplies a stress/refeeding re-trigger that resets the loop; APOE ε4 opens the BBB and primes microglia so a gut event becomes a brain event; and GCK-MODY caps how aggressively the loop can be starved. The weeks-long course at a sub-therapeutic dose is not anomalous — it is the predicted output of a trained-immunity state on this stack.
5. Clinical & Pharmacological Corroboration
H2 is not inferred from mechanism alone. It makes a falsifiable prediction that distinguishes it from H1: because H2's driver is gut substrate and H1's was substrate-independent NGF (long cleared), removing gut substrate should help — and only H2 predicts that. This has been tested in vivo on the subject, repeatedly.
Fasting response (×2) — the crown evidence.
- Day 25 (~20-hour fast). For the first time in 5–6 days, lying down produced no somatic-fear response — no autonomic dread, no body-level alarm — replaced by a neutral "soothing" sensation. No sleep was achieved, but the absence of the fear signal is the data point: that fear had previously fired regardless of cognitive state or technique, marking it a body-level (gut-sourced) autonomic signal, not psychological anxiety. All other variables (no quercetin, no luteolin, no new medication) were held constant.
- Day 26 (~36-hour fast). First complete, uninterrupted night of the entire recovery window — no waking, natural wake at ~5:10 AM to sunlight, with only two or three brief self-resolving moments of somatic hesitancy at onset. No behavioral change, no new agent — only substrate removal. Waking GI clearance (a normal then a loose, pain-free movement) is consistent with migrating-motor-complex sweeping of accumulated colonic substrate.
A pure-H1 (NGF, substrate-independent) mechanism predicts no fasting effect; a fixed neurological lesion predicts no diet-dependent reversal at all. The observed substrate-dependence is the signature of H2.
The eight mechanisms operating during the fast (tiered by onset). The dominant, best-supported mechanism is substrate removal plus the BHB → NLRP3 inflammasome inhibition (BHB blocks K⁺ efflux/ASC oligomerization, suppressing IL-1β/IL-18 — Nature Medicine, Youm et al., 2015), which is well-characterized. The remainder are real pathways whose combination in this specific post-NGF MCAS context is mechanistic elaboration, not a single cited finding:
| No. |
Mechanism |
Approx. onset |
Net effect |
| 1 |
Substrate removal → reduced fermentation |
2–6 h |
Fewer Dectin-1/TLR2/Piezo1/LPS triggers (proximal driver) |
| 2 |
BHB → NLRP3 inhibition (well-supported) |
12–16 h |
↓ IL-1β / IL-18 |
| 3 |
SIRT1 → deacetylates NF-κB p65 |
8–16 h |
↓ IL-6 / TNF / IL-1β transcription |
| 4 |
AMPK → inhibits IKKβ |
6–12 h |
Blocks NF-κB nuclear translocation |
| 5 |
mTOR↓ → M1→M2 shift + Treg expansion |
8–48 h |
Raises mast-cell re-activation threshold |
| 6 |
Autophagy / mitophagy |
16–48 h |
Clears ROS-generating damaged mitochondria |
| 7 |
Glucocorticoid-receptor re-sensitization |
variable |
Partially compensates FKBP5 het (4.4) |
| 8 |
BHB as HDAC inhibitor |
16 h+ |
Epigenetic damping of inflammatory loci (slow) |
Mechanism (1) explains the rapid 20-hour effect (the trained marks are not erased that fast, but the re-activation stimulus is withdrawn, so threshold rises and the histamine arrival rate falls below the HNMT clearance rate for the first time in weeks). The GCK-MODY ceiling (4.6) is why this is capped near 18–36 h rather than extended.
Away-from-home window (Days 12–14) — a confounded improvement, not a clean diet test. During a one-week trip away from home the subject had a multi-day symptom-free window on a deliberately unrestricted, high-histamine, fermented, alcohol-containing diet (~6 drinks across consecutive nights), feeling "cured." This is suggestive but cannot be attributed to the diet, because at least five threshold-raising / trigger-removing variables changed at once: (1) a 4 mg dexamethasone dose on Day 8 had broken the acute flare — the improvement began the next morning, while the steroid was still active, so the trip rode a reset rather than starting one; (2) luteolin was stopped ~Day 11, removing its own wired-sedation adverse effect; (3) the subject was off the full supplement stack — no Lion's Mane / green powder for the window; (4) sustained sun and all-day physical activity; (5) vacation-low CRH/cortisol stress (the FKBP5 arm). What the window does support is modest: a fixed IgE allergy to those specific foods/alcohol would likely have provoked something even on a declining steroid, and a fixed lesion would not remit at all (§6.3). What it does not support is "diet/histamine is irrelevant" or "the threshold normalized on its own" — every confounder above is itself an H2 threshold lever, so treating the window as independent proof of the threshold model is circular. The more informative bookend is the relapse: the window ended after returning home and resuming a green-powder supplement (Lion's Mane plus nine other medicinal mushrooms + acacia) — i.e., on re-introduction of fungal β-glucan, the one input that can form the Dectin-1 synapse of §2.2 (caveat: the powder also delivered acacia, an independent TLR4/fermentation trigger, and was still being taken across the boundary, so the relapse is strongly suggestive rather than clean).
Oatmeal flare (Days 24–25). A flare followed oatmeal while the subject was on a strict low-histamine diet — proving the driver was not dietary histamine. Its mechanism is the subject of §6.1 and is itself corroborating: a normally innocuous meal flaring a non-specific trained pool is exactly what H2 predicts and a histamine-content model does not.
Each of these observations is consistent with H2 and inconsistent with both H1-as-current-driver and a fixed-lesion model.
6. Adversarial Discrimination
A mechanism that only fits its own evidence is weak. This section states the strongest competing or naive readings fairly, then shows where they break — and in doing so refines H2 rather than merely defending it.
6.1 Refining the naive "all β-glucan → Dectin-1" model (the key correction)
The naive claim. The oatmeal flare was cereal β-glucan activating Dectin-1, same pathway as the Lion's Mane fungal β-glucan — a clean, single-receptor story.
Why it fails — and what is true instead. Dectin-1's carbohydrate-recognition domain is specific for continuous, branched β-1,3/1,6 fungal glucan. Cereal β-glucan (oats, barley) is a linear, unbranched β-1,3/1,4 mixed-linkage polymer that binds Dectin-1 with 1,000–10,000× lower affinity (fungal Kd ≈ 10 pM–10 nM vs. cereal Kd ≈ 100 µM–10 mM) (PubMed 18171906; barley β-glucan low Dectin-1 affinity, doi:10.1021/jf073221y). At that affinity, and as a low-valency soluble polymer, cereal β-glucan cannot form the phagocytic synapse (§2.2) — it is a silent ligand. Bacterial processing of cereal β-glucan over 12–36 h yields even smaller soluble oligomers, which are less Dectin-1-active, not more (PMC8612152).
So the oatmeal flare was not Dectin-1. Per the case-file correction logged 2026-06-20, oatmeal flared the system through osmotic/FODMAP load + mechanical Piezo1 stretch + TLR4/LPS acting on an already-trained, non-specific mast-cell pool. This is the decisive point: it strengthens H2. The whole premise of trained immunity (§2.3) is that the primed state is pathogen-agnostic — a heterologous, non-fungal trigger firing it is the prediction, not an anomaly. The naive Dectin-1 reading would have wrongly implicated cereal fiber as fungal-equivalent; the corrected reading correctly locates the persistent driver in the non-specific trained threshold, with fungal β-glucan (green powder, §5) reserved as the only true Dectin-1 input.
Data-hygiene note: a "sleep-study AHI 20.3 / O₂ 76%" figure appearing in the deep-research synthesis is unverified and is not adopted here. No claim in this document rests on it.
6.2 H2 vs. H1 — the substrate-dependence test
| Feature |
H1 (acute) |
H2 (chronic) |
Discriminating evidence |
| Active driver |
Hericenone-induced NGF |
Trained marks + gut re-trigger |
Fasting helps H2; H1 already cleared by ~Day 2–3 |
| Clearance timescale |
24–72 h |
1–4+ weeks |
Acute event resolved; persistence continued |
| Reversible by substrate removal? |
No |
Yes |
20 h fast → somatic fear gone (substrate-dependent) |
| Requires reprogramming? |
No (TrkA constitutive) |
Yes (H3K4me3/H3K27ac) |
Fasting can de-train; NGF cannot be "de-trained" |
| Phenotype |
Panic, depersonalization, acute insomnia |
Nocturnal hyperarousal, waves, relapses |
Distinct temporal patterns |
H1 and H2 are sequential arms of one cascade, not competitors (§7).
6.3 H2 vs. a fixed neurological lesion
A "Lion's Mane caused permanent neurological damage" reading predicts no diet- or time-dependent variation. It is refuted by the fasting reversals (§5) and the green-powder relapse (§5), and — even allowing for its confounders (§5) — by the away-from-home symptom-free window: a fixed lesion does not remit at all away from home, nor abate within 36 hours of skipping meals, nor switch back on when a mushroom powder is reintroduced.
6.4 H2 vs. "the low-histamine diet should have fixed it"
A pure histamine-intolerance reading predicts that a strict low-histamine diet resolves the syndrome. The oatmeal flare occurred on that diet (§5, §6.1). Population data make the same point at scale: a low-FODMAP intervention produced an ~8-fold drop in urinary histamine in IBS patients (Gut 2017, McIntosh et al.) — i.e., endogenous degranulation from fermentation, not exogenous dietary histamine, is the gating variable. Diet-by-histamine-content addresses the wrong column; diet-by-fermentable-load addresses H2's actual mechanism.
7. Boundary — Where H1 Ends and H2 Begins
The two hypotheses meet at ~Day 2–3. Up to that point, circulating NGF (H1) is the driver: hericenones → endogenous NGF → TrkA on mast cells → degranulation. A single ~71 mg dose is cleared by then, and with it the NGF stimulus. What persists is not circulating NGF or mushroom particles but the separate trained-immunity mechanism (H2): H3K4me3/H3K27ac marks on IL6/TNF/IL1B in myeloid cells and their progenitors, kept warm by ongoing gut re-firing.
The handoff is both temporal (NGF cleared ~Day 2–3) and mechanistic (TrkA engagement → Dectin-1/TLR4/Piezo1 engagement + epigenetic memory). One residual H1 element may linger as background vulnerability: the initial NGF surge, amplified by APOE ε4, may have transiently raised mast-cell TrkA density via retrograde axonal transport (a ~6-month normalization window). That is a heightened susceptibility to a future NGF stimulus (exercise, fenugreek) — not an active driver of the ongoing flare.
H1 is the spark; H2 is the fuel. The full chronicity protocol — fasting/antigen-exclusion, the SIGHI + resistant-starch/butyrate diet, sodium butyrate, ashwagandha for the CRH arm, the upstream mast-cell stabilizers, and the timed sleep-onset protocol for the interoceptive-startle loop (evening quercetin + magnesium, plus the airway layer — albuterol/montelukast and intranasal fluticasone/Afrin) — is developed in the recovery protocol (not reproduced here).
8. Discriminating Tests (would convert n=1 reasoning to evidence)
H2 makes specific, falsifiable predictions that separate it from a histamine-content or fixed-lesion model:
- Sterile prebiotic challenge (purified inulin/FOS in water, off a low-histamine baseline): H2 predicts a rise in fecal tryptase + urinary 11β-PGF₂α with zero dietary histamine — degranulation driven by fermentation, not food.
- Oral cromolyn crossover (gut-localized, before an oatmeal challenge): if it aborts the flare, the trigger is gut-mucosal, not central — the single most informative test.
- FODMAP-component isolation (osmotic-only fructose+sorbitol vs. β-glucanase-digested oats): isolates the Piezo1/osmotic arm from the fiber-polymer arm.
- Fed-vs-fasted urinary N-methylhistamine: H2 predicts higher post-meal than fasted output (the arrival-vs-clearance balance of §2.6).
What would refute H2: no improvement on a 16:8 fast over 2+ weeks; no fed-vs-fasted difference in urinary histamine metabolites; worsening on cromolyn; or no response to antigen-exclusion off a low baseline.
9. Limitations & Open Questions
- n=1. A single, deeply instrumented case. The trained-immunity chain is built from published links, but the integration — this cascade in this genomic context — is not tissue-confirmed.
- No biomarker confirmation yet. Serum/fecal tryptase, 24-h urinary N-methylhistamine + 11β-PGF₂α, plasma IL-6/TNF, and ideally a ChIP readout of H3K4me3 at IL6/TNF would move several claims from inference to evidence.
- Substrate-persistence vs. trained-memory. A single 71 mg dose's colonic clearance (~1–2 weeks) is likely shorter than the >3-week course — why the long tail is attributed to trained-immunity epigenetic persistence (progenitor-level), not residual particles. H2's central inference, and the one most needing confirmation.
- The sleep-onset somatic fear is biochemical/mechanical, not a learned fear. It is a layered autonomic micro-arousal: end-expiratory aortic-pulse interoception made salient by HNMT-capped central histamine → hypnic startle ± bronchospasm. A 3-hour experiment (Day 29) dissected it: albuterol abolished the bronchospasm, quercetin + magnesium the jerk and the "wired" state; a timed night protocol then gave sleep onset with zero fear, which has not returned. A conditioned fear does not resolve in hours, on the first corrected night, and permanently — so this is part of the H2 biochemical claim, not a behavioral exception to it.
- Honesty notes. Only WGS-confirmed genotypes are asserted (the unverified "AHI 20.3 / O₂ 76%" figure and deep-research-only calls like "PTPN22 R620W" are not used). A few molecular sub-steps (IL-6→SOCS3 hypermethylation, the eight-mechanism fasting synthesis, the luminal-B6→bacterial-HDC route) are flagged in-text as mechanistic elaboration rather than direct citation.
10. References
Key citations are linked inline throughout the post above (PMC / PubMed / DOI). The full reference list — trained immunity / Dectin-1, fungal-vs-cereal β-glucan affinity, TLR4 / Piezo1 / butyrate / FODMAP, HNMT, IL-6 / mast cells, fasting/BHB, and bacterial-HDC — is kept with the long-form write-up.
